Pharsight

1. List of Injectafer drug patents

Application	Filing Date	Opposition Party	Legal Status
EP07716309A	2017-04-20	STADA Arzneimittel AG	Granted and Under Opposition
EP07716309A	2017-04-20	Taylor Wessing LLP	Granted and Under Opposition
EP07716309A	2017-04-20	Generics [U.K.] Limited	Granted and Under Opposition
EP07716309A	2017-04-19	HGF Limited	Granted and Under Opposition
EP07716309A	2017-04-18	TEVA PHARMACEUTICAL INDUSTRIES, LTD.	Granted and Under Opposition
EP07716309A	2017-04-13	Pharmacosmos Holding A/S	Granted and Under Opposition
EP07716309A	2017-04-10	Hoffmann Eitle	Granted and Under Opposition
EP10194332A	2013-02-27	Kernebeck Patentanwalts GmbH	Opposition rejected

Patent	Proceeding Filing Date	Status	Respondent	Petitioner
US7754702	June, 2015	FWD Entered	Luitpold Pharmaceuticals, Inc.	Pharmacosmos A/S
US8895612	June, 2015	Terminated-Denied	Luitpold Pharmaceuticals, Inc.	Pharmacosmos A/S

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11291645	AM REGENT	Aqueous iron carbohydrate complexes, their production and medicaments containing them	Oct, 2023 (4 months from now)
US11590097	AM REGENT	Aqueous iron carbohydrate complexes, their production and medicaments containing them	Oct, 2023 (4 months from now)
US11123321	AM REGENT	Aqueous iron carbohydrate complexes, their production and medicaments containing them	Oct, 2023 (4 months from now)
US9376505	AM REGENT	Aqueous iron carbohydrate complexes, their production and medicaments containing them	Oct, 2023 (4 months from now)
US7612109	AM REGENT	Water-soluble iron-carbohydrate complexes, production thereof, and medicaments containing said complexes	Feb, 2024 (8 months from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11433091	AM REGENT	Methods and compositions for administration of iron	Jan, 2027 (3 years from now)
US8895612	AM REGENT	Methods and compositions for administration of iron	Jan, 2027 (3 years from now)
US11478502	AM REGENT	Methods and compositions for administration of iron	Jan, 2027 (3 years from now)
US7754702	AM REGENT	Methods and compositions for administration of iron	Feb, 2028 (4 years from now)

Do you want to check out INJECTAFER patents from before 2022?

Exclusivity	Exclusivity Expiration
New Strength (NS)	Apr 28, 2024
New Patient Population (NPP)	Nov 19, 2024

Drugs and Companies using FERRIC CARBOXYMALTOSE ingredient

Market Authorisation Date: 25 July, 2013

Treatment: Method of treating ida in adult patients with non-dialysis dependent chronic kidney disease & weighing at least 46.7 kg by intravenously administering ferric carboxymaltose to provide at least 0.7 g o...

Dosage: SOLUTION;INTRAVENOUS

Strength	Submission Date	ANDA(s) Filed	Last patent expiry
100 mg/2 mL	23 Sep, 2022	1	15 Feb, 2028
750 mg/15 mL	27 Mar, 2019	1	15 Feb, 2028
1 g/20 mL	15 Feb, 2022	1	15 Feb, 2028

Strength	Dosage	Availability
1GM IRON/20ML (50MG IRON/ML)	SOLUTION;INTRAVENOUS	Prescription
750MG IRON/15ML (50MG IRON/ML)	SOLUTION;INTRAVENOUS	Prescription
100MG IRON/2ML (50MG IRON/ML)	SOLUTION;INTRAVENOUS	Prescription
500MG IRON/10ML (50MG IRON/ML)	SOLUTION;INTRAVENOUS	Prescription